Skip to content

Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy

Patients' Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy (SCSE-OAC): A Bilingual/Multi-national Mixed-method Validation Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05820854
Acronym
SCSE-OAC
Enrollment
312
Registered
2023-04-20
Start date
2023-11-30
Completion date
2025-02-28
Last updated
2023-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulants, Self Confidence, Self Efficacy

Brief summary

This study aims to develop and validate an index measurement tool to assess the patient's self-care self-efficacy in managing oral anticoagulation therapy (OAC). The index measure (i.e., SCSE-OAC) will be tested for its cross-cultural validity and reliability for the English and Italian-speaking population. For these reasons, a multi-phase and mixed-method observational and cross-sectional study design will be conducted.

Detailed description

Oral anticoagulation therapy (OAC) is the most suitable treatment worldwide for the primary and secondary prevention of thromboembolism and stroke in patients with non-valvular atrial fibrillation (NVAF). However, the strategies to provide an optimal quality of anticoagulation control are still an open challenge for healthcare professionals. In this regard, understanding the health determinants underline the patient's adherence is fundamental in the research field to develop personalized patient-centered education interventions in clinical practice and consequently avoid low treatment adherence. Among these health determinants (e.g., patients' knowledge, health literacy, beliefs, etc), the patients' self-efficacy is underreported because a specific tool is not yet available to measure patients' self-efficacy regarding the health behaviors challenges in OAC self-care management. The primary aim of this study is to develop the patients' self-care self-efficacy index in oral anticoagulation therapy management (SCSE-OAC) in adults with non-valvular atrial fibrillation and provide cross-cultural validity and reliability of the developed index measure. More specifically, to assess the internal validity of the SCSE-OAC, content and construct validity proprieties will be tested for each translated version of the SECSE-OAC, as well as its reliability and invariance characteristics.

Interventions

OTHERSelf-assess and reporting self-care self-efficacy levels

Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.

Sponsors

IRCCS Policlinico S. Donato
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 years * Diagnosis of non-valvular atrial fibrillation * Outpatients * Treating with any OAC for at least three months before enrollment * Patients willing to participate in the study and provide informed consent

Exclusion criteria

* Patients treated with OAC for a brief period (i.e., less than three months) * Patients with serious comorbidity (i.e, Charlson Comorbidity Index, ICC \> 4) * Patients who have suspended OAC for surgery in the last three months * Cognitive impairment (assessed using six-item screener, SIS \< 4)

Design outcomes

Primary

MeasureTime frameDescription
SCSE-OAC indexdata collection will perform at the first 1 day patient visitThe SCSE-OAC measurement index will provide evidence about the level patients perceive in their skills in facing daily challenges in managing their oral anticoagulation therapy. Furthermore, evidence of the validity and reliability of the SCSE-OAC tool will be provided for each native-speaking country involved in the study.

Contacts

Primary ContactArianna Magon
arianna.magon@grupposandonato.it3313812318

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026